Novoxel® was founded in 2011 to transform both aesthetic and medical treatments through innovative technology. Our mission focuses on enhancing patient experience through excellent clinical results, minimal downtime, and cost efficiency.
Our patented TMA® technology stands out in both aesthetic and medical applications. Our latest breakthrough device to receive FDA-clearance is the Tixel i® for dry eye treatment . Tixel i delivers 2-minute MGD relief through precisely controlled thermo-mechanical action, offering practices a delegable, long-lasting solution without disposables.
The Tixel® family of products uniquely serves multiple applications, from dry eye treatment to skin rejuvenation, usable on all skin types year-round. Our solutions are backed by extensive clinical research, with safety and efficacy documented in dozens of peer-reviewed publications.
With over 65 patents and presence in more than 50 countries, Novoxel continues to invest heavily in R&D and IP protection. Our Knoxville, Tennessee headquarters, established in 2024, is led by a management team with 90+ years of combined industry experience, driving innovation in both aesthetic and medical device markets.
Legend
Available Timeslot
Scheduled Appointment
Personal Appointments
Appointment Request
Blocked Timeslot
Restricted Timeslot